Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | HTT | P42858 | 2/20 | 0.76 |
| ▸ | AKT1 | P31749 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 4/20 | 0.69 |
| ▸ | GFER | P55789 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13453546 | 0.85 | KMT2A (0.85) | P2RY1KMT2AALDH1A1HTTAKT1 | |
| SCHEMBL328334 | 0.83 | ALOX12 (0.81) | P2RY1KMT2AALDH1A1HTTAKT1 | |
| SCHEMBL10031613 | 0.83 | ALDH1A1 (0.80) | P2RY1KMT2AALDH1A1HTTAKT1 | |
| SCHEMBL13453485 | 0.81 | KMT2A (0.80) | P2RY1KMT2AALDH1A1HTTAKT1 | |
| SCHEMBL13453548 | 0.81 | MEN1 (0.71) | P2RY1KMT2AALDH1A1HTTPOLB | |
| SCHEMBL24274737 | 0.81 | KMT2A (1.00) | KMT2AALDH1A1HTTAKT1SMN1; SMN2 | |
| SCHEMBL13453526 | 0.79 | KMT2A (0.82) | P2RY1KMT2AALDH1A1HTTAKT1 | |
| SCHEMBL328330 | 0.79 | ALDH1A1 (0.74) | P2RY1KMT2AALDH1A1HTTAKT1 | |
| SCHEMBL7824834 | 0.79 | ALDH1A1 (0.78) | P2RY1KMT2AALDH1A1HTTAKT1 | |
| SCHEMBL328331 | 0.79 | AKT1 (1.00) | P2RY1KMT2AALDH1A1HTTAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932300-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | P2RY1 3079/4885KMT2A 761/4885ALDH1A1 3464/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | P2RY1 3079/4885KMT2A 761/4885ALDH1A1 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.